World Journal of Gastroenterology Impact Factor & Information

Publisher: Zhongguo Zhong xi yi jie he yan jiu hui

Journal description

WJG is an international learned journal of gastroenterology. It is published in English bimonthly and distributed worldwide, and it aims to strengthen international exchanges of modern and traditional gastroenterology, to promote the development of gastroenterology, and to make contributions to human health. WJG is the only international journal of gastroenterology published in English based in China. It mainly publishes original papers of basic research and clinical studies in gastroenterology from all of the world. Original articles with international competitiveness, articles from projects supported by scientific grants, original articles of traditional Chinese digestive medicine and herbs, of acupuncture, of ethinomedicine, and of combined traditional and modern digestive medicine are published with priority. Commentaries, literature reviews, rapid reports, clinical experience, and case reports of rare diseases are published preferentially as well.

Current impact factor: 2.37

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 2.369
2013 Impact Factor 2.433
2012 Impact Factor 2.547
2011 Impact Factor 2.471
2010 Impact Factor 2.24
2009 Impact Factor 2.092
2008 Impact Factor 2.081
2003 Impact Factor 3.318
2002 Impact Factor 2.532
2001 Impact Factor 1.445
2000 Impact Factor 0.993

Impact factor over time

Impact factor

Additional details

5-year impact 2.67
Cited half-life 5.80
Immediacy index 0.35
Eigenfactor 0.05
Article influence 0.65
Website World Journal of Gastroenterology website
Other titles World journal of gastroenterology (Online), WJG, Shih chieh wei ch'ang ping hsüeh tsa chih
ISSN 1007-9327
OCLC 60638475
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Addiction to synthetic cannabinoids (SCs) is a growing social and health problem worldwide. Chronic use of SCs may cause adverse effects in the gastrointestinal system. We describe a very rare case of acute gastric dilatation (AGD) and hepatic portal venous gas (HPVG), with findings of acute abdomen resulting from chronic use of a SC, Bonzai. AGD and HPVG were detected by computerized tomography examination. Patchy mucosal ischemia was seen in endoscopic examination. Despite the findings of an acute abdomen, a non-surgical approach with nasogastric decompression, antibiotic therapy, and close radiologic and endoscopic follow-up was preferred in the presented case. Clinical and radiologic findings decreased dramatically on the first day, and endoscopic findings gradually disappeared over 7 d. In conclusion, this case shows that chronic use of a SC may cause AGD and accompanying HPVG, which can be managed non-surgically despite the findings of acute abdomen. Keywords: Acute abdomen, Acute gastric dilatation, Bonzai, Synthetic cannabinoid, Hepatic portal venous gas
    World Journal of Gastroenterology 10/2015; 21(37):10704. DOI:10.3748/wjg.v21.i37.10704
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis C virus (HCV) is a major health problem around globe with high morbidity and mortality. About 185 million people are living with HCV out which 80% are living in low and middle income countries. With the development of new highly effective treatment for HCV it is considered that the elimination of HCV is only one step away. The major problem with new treatment is its high price. The price of Sofosbuvir based treatment for one patient in United States is US$ 85000–110000. While the actual production cost of 12 wk direct-acting antiviral regimen is less than US$ 250. Another major hindrance in HCV eradication is the screening of blood transfusion from laboratories having no quality check. Due to lack of HCV screening, 75% of people in United States with HCV infection are unaware of their infection. The control of massive HCV pandemic requires financial investment, political will and support from medical, pharmaceutical and civil organizations around the globe.
    World Journal of Gastroenterology 09/2015; In Press.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pediatric intestinal motility disorders affect many children and thus not only impose a significant impact on pediatric health care in general but also on the quality of life of the affected patient. Furthermore, some of these conditions might also have implications for adulthood. Pediatric intestinal motility disorders frequently present as chronic constipation in toddler age children. Most of these conditions are functional, meaning that constipation does not have an organic etiology, but in 5% of the cases, an underlying, clearly organic disorder can be identified. Patients with organic causes for intestinal motility disorders usually present in early infancy or even right after birth. The most striking clinical feature of children with severe intestinal motility disorders is the delayed passage of meconium in the newborn period. This sign is highly indicative of the presence of Hirschsprung disease (HD), which is the most frequent congenital disorder of intestinal motility. HD is a rare but important congenital disease and the most significant entity of pediatric intestinal motility disorders. The etiology and pathogenesis of HD have been extensively studied over the last several decades. A defect in neural crest derived cell migration has been proven as an underlying cause of HD, leading to an aganglionic distal end of the gut. Numerous basic science and clinical research related studies have been conducted to better diagnose and treat HD. Resection of the aganglionic bowel remains the gold standard for treatment of HD. Most recent studies show, at least experimentally, the possibility of a stem cell based therapy for HD. This editorial also includes rare causes of pediatric intestinal motility disorders such as hypoganglionosis, dysganglionosis, chronic intestinal pseudo-obstruction and ganglioneuromatosis in multiple endocrine metaplasia. Underlying organic pathologies are rare in pediatric intestinal motility disorders but must be recognized as early as possible.
    World Journal of Gastroenterology 09/2015; 21(33):9683. DOI:10.3748/wjg.v21.i33.9683
  • [Show abstract] [Hide abstract]
    ABSTRACT: Liver cancer is one of the world's most common cancers and the second leading cause of cancer deaths. Hepatocellular carcinoma (HCC), a primary hepatic cancer, accounts for 90%–95% of liver cancer cases. The pathogenesis of HCC consists of a stepwise process of liver damage that extends over decades, which is from hepatitis, fatty liver, fibrosis, and cirrhosis before developing fully into HCC. Multiple risk factors are highly correlated with HCC, including infection with the hepatitis B or C viruses, alcohol abuse, aflatoxin exposure, and metabolic diseases. Over the last decade, genetic alterations, which include the regulation of multiple oncogenes or tumor suppressor genes and the activation of tumorigenesis-related pathways, have also been identified as important factors in HCC. Recently, zebrafish have become an important living vertebrate organism, especially in translational medicine research. In previous carcinogen treatment experiments, it has been found that tumors induced in zebrafish have many similarities to tumors found in humans. Several zebrafish models have been developed to provide insight into the disease pathogenesis of liver cancer characteristics and the related drug discovery and toxicology, and to enable the evaluation of novel small-molecule inhibitors. This review will focus on illustrative examples involving the application of zebrafish models to the study of human liver disease and HCC, including in studies involving transgenesis, genome editing technology, the xenograft method, drug discovery, and drug-induced toxic liver injury.
    World Journal of Gastroenterology 09/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis D virus (HDV) is the smallest single stranded RNA virus infecting humans. The hepatitis B surface antigen envelope protein protects the HDV nucleocapsid antigen and provides a means for the virus to enter and exit the hepatocyte. Hepatitis B and D viruses exploit the human sodium taurocholate co-transporting polypeptide (NTCP), a receptor, for their entry into hepatocytes. Prenylation of the large delta antigen is a critical determinant of HDV particle assembly. Treatment with pegylated interferon results in sustained virological response six months post-treatment in one fourth of the patients. Nucleos(t)ide analogs (NAs) have been widely tested in hepatitis delta, but they appear to be ineffective. Combination treatment of NAs with interferon also proved to be disappointing so there is a need for novel therapeutic options. The receptor function of NTCP is blocked by Myrcludex B, a synthetic N-acylated preS1 lipopeptide that competes with infectious virions for receptor binding. There are already some approved drugs available, including irbesartan, ezetimibe, and ritonavir and cyclosporin A, with documented inhibitory effects on NTCP's metabolic function. These drugs may have a role in HDV treatment. Interference with host-mediated post-translational changes of proteins that are crucial to the HDV life cycle, such as prenylation may become an important tool to control HDV infection and prevent replication. Lonafarnib, a prenylation inhibitor significantly reduces virus levels in hepatitis delta patients. Antisense oligodeoxynucleotides which are complementary to genomic HDV ribozyme self-cleavage site and stem I regions can inhibit genomic HDV ribozyme activity.
    World Journal of Gastroenterology 08/2015; 21(32):9461. DOI:10.3748/wjg.v21.i32.9461